CARDIOL THERAPEUTICS INC-A (CRDL) Stock Fundamental Analysis

NASDAQ:CRDL • CA14161Y2006

1.02 USD
-0.05 (-4.67%)
At close: Feb 27, 2026
1.05 USD
+0.03 (+2.94%)
After Hours: 2/27/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall CRDL gets a fundamental rating of 1 out of 10. We evaluated CRDL against 192 industry peers in the Pharmaceuticals industry. CRDL has a bad profitability rating. Also its financial health evaluation is rather negative. CRDL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CRDL has reported negative net income.
  • In the past year CRDL has reported a negative cash flow from operations.
  • CRDL had negative earnings in each of the past 5 years.
  • In the past 5 years CRDL always reported negative operating cash flow.
CRDL Yearly Net Income VS EBIT VS OCF VS FCFCRDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -268.65%, CRDL is doing worse than 90.67% of the companies in the same industry.
  • CRDL has a worse Return On Equity (-363.82%) than 76.17% of its industry peers.
Industry RankSector Rank
ROA -268.65%
ROE -363.82%
ROIC N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
CRDL Yearly ROA, ROE, ROICCRDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDL Yearly Profit, Operating, Gross MarginsCRDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • CRDL has more shares outstanding than it did 1 year ago.
  • CRDL has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for CRDL is higher compared to a year ago.
CRDL Yearly Shares OutstandingCRDL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRDL Yearly Total Debt VS Total AssetsCRDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -3.04, we must say that CRDL is in the distress zone and has some risk of bankruptcy.
  • CRDL has a Altman-Z score (-3.04) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.01 indicates that CRDL is not too dependend on debt financing.
  • CRDL's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. CRDL outperforms 58.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -3.04
ROIC/WACCN/A
WACCN/A
CRDL Yearly LT Debt VS Equity VS FCFCRDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 3.89 indicates that CRDL has no problem at all paying its short term obligations.
  • CRDL has a Current ratio (3.89) which is comparable to the rest of the industry.
  • A Quick Ratio of 3.89 indicates that CRDL has no problem at all paying its short term obligations.
  • CRDL has a Quick ratio of 3.89. This is in the better half of the industry: CRDL outperforms 60.62% of its industry peers.
Industry RankSector Rank
Current Ratio 3.89
Quick Ratio 3.89
CRDL Yearly Current Assets VS Current LiabilitesCRDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • CRDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.07%, which is quite impressive.
EPS 1Y (TTM)24.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CRDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.53% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22%
EPS Next 2Y-5.51%
EPS Next 3Y19.19%
EPS Next 5Y24.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRDL Yearly Revenue VS EstimatesCRDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
CRDL Yearly EPS VS EstimatesCRDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 0.5 -0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRDL. In the last year negative earnings were reported.
  • Also next year CRDL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDL Price Earnings VS Forward Price EarningsCRDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDL Per share dataCRDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • CRDL's earnings are expected to grow with 19.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.51%
EPS Next 3Y19.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CRDL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CARDIOL THERAPEUTICS INC-A

NASDAQ:CRDL (2/27/2026, 8:00:00 PM)

After market: 1.05 +0.03 (+2.94%)

1.02

-0.05 (-4.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners11.38%
Inst Owner Change31.58%
Ins Owners4.3%
Ins Owner ChangeN/A
Market Cap113.91M
Revenue(TTM)N/A
Net Income(TTM)-34.78M
Analysts82.5
Price Target7 (586.27%)
Short Float %1.89%
Short Ratio5.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.21%
Min EPS beat(2)-30.72%
Max EPS beat(2)18.3%
EPS beat(4)3
Avg EPS beat(4)12.55%
Min EPS beat(4)-30.72%
Max EPS beat(4)32.64%
EPS beat(8)5
Avg EPS beat(8)3.01%
EPS beat(12)9
Avg EPS beat(12)9.06%
EPS beat(16)13
Avg EPS beat(16)12.38%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.71%
PT rev (3m)-0.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 16.29
P/tB 16.29
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -268.65%
ROE -363.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.89
Quick Ratio 3.89
Altman-Z -3.04
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.14%
Cap/Depr(5y)17.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y22%
EPS Next 2Y-5.51%
EPS Next 3Y19.19%
EPS Next 5Y24.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.92%
EBIT Next 3Y13.88%
EBIT Next 5Y17.77%
FCF growth 1Y12.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.36%
OCF growth 3YN/A
OCF growth 5YN/A

CARDIOL THERAPEUTICS INC-A / CRDL FAQ

What is the ChartMill fundamental rating of CARDIOL THERAPEUTICS INC-A (CRDL) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CRDL.


What is the valuation status of CARDIOL THERAPEUTICS INC-A (CRDL) stock?

ChartMill assigns a valuation rating of 0 / 10 to CARDIOL THERAPEUTICS INC-A (CRDL). This can be considered as Overvalued.


Can you provide the profitability details for CARDIOL THERAPEUTICS INC-A?

CARDIOL THERAPEUTICS INC-A (CRDL) has a profitability rating of 0 / 10.


What is the expected EPS growth for CARDIOL THERAPEUTICS INC-A (CRDL) stock?

The Earnings per Share (EPS) of CARDIOL THERAPEUTICS INC-A (CRDL) is expected to grow by 22% in the next year.